Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

J&J has reported that interim data from Phase I/IIa sub-study of Covid-19 vaccine showed robust immune responses against the Delta...

Covid-19 mRNA vaccines in children are currently being trialled for safety and efficacy. The data looks favourable but risks...

Covid-19 mRNA vaccines in children are currently being trialled for safety and efficacy. The data looks favourable but risks...

Covid-19 mRNA vaccines in children are currently being trialled for safety and efficacy. The data looks favourable but risks...

  • "Based on data in recipients over 12 years old, the overall favourable safety and efficacy of these mRNA vaccines should be similar in under-12s, Yale Medicine vaccinologist and pediatric infectious disease specialist Dr Inci Yildirim said." https://t.co/qfbJc9dByN - view on twitter

A new paradigm for HIV treatment is on the horizon as FDA gives nod for startup to begin trials of CRISPR-based gene therapy as...

A new paradigm for HIV treatment is on the horizon as FDA gives nod for startup to begin trials of CRISPR-based gene therapy as...

Pfizer has selected a lower dose of its Covid-19 vaccine for assessment in Phase II/III clinical trial involving children aged below 12...

Merck and Ridgeback Biotherapeutics have commenced a Phase III MOVe-AHEAD trial of their oral drug, molnupiravir, to prevent...

The candidate, mRNA-1644, is based on the same mRNA platform as Moderna’s highly effective Covid-19 jab Moderna could start trials of its experimental mRNA...